Background
Materials and methods
Animal studies
Sourcing of human tumor tissue
Number | |
---|---|
Age
| |
Mean | 62 years |
Range | 46 – 72 years |
Gender
| |
Male | 2 |
Female | 1 |
Location of primary tumor
| |
Stomach | 0 |
Small bowel | 3 |
Duodenum | 1 |
Jejunum | 1 |
Ileum | 1 |
Presentation
| |
Abdominal pain | 2 |
Bleeding | 1 |
Recurrence/metastasis on CT scan | 1 |
Previous imatinib therapy
| |
Yes | 1 |
No | 2 |
Primary tumor size
| |
Mean | 19.2 cm |
Range | 6.5 – 38.0 cm |
Mitotic index (mitoses per 5 mm
2
)
| |
Mean | 32.7 |
Range | 10 – 65 |
Peritoneal metastases
| |
Yes | 2 |
No | 1 |
KIT exon mutational analysis
| |
Exon 9 | 2 |
Exon 11 | 1 |
Exon 13/14 | 0 |
Exon 17/18 | 0 |
Implantation of patient-derived xenografts
Number | Percent (%) | |
---|---|---|
Age at implantation
| ||
Mean ± standard deviation | 9.1 ± 7.3 weeks | |
Range | 5.7 – 30.6 weeks | |
Gender
| ||
Male | 8 | 32.0% |
Female | 17 | 68.0% |
Genotype
| ||
NOD-scid (NS) | 10 | 40.0% |
NOD-scid gamma (NSG) | 15 | 60.0% |
Tumor development
| ||
Yes | 21 | 84.0% |
No | 4 | 16.0% |
Passages
| ||
0 (Primary, successes/total) | 11/14 | 85.7% |
1 (Successes/total) | 5/6 | 83.3% |
2 (Successes/Total) | 5/5 | 100.0% |
Location of implantation
| ||
Successful implantations/total | 21/25 | 84.0% |
Liver (successes/total) | 9/10 | 90.0% |
Renal capsule (successes/total) | 9/10 | 90.0% |
Lesser sac (successes/total) | 2/3 | 66.7% |
Gastric wall (successes/total) | 1/2 | 50.0% |